HR Execs on the Move

ARCA biopharma

www.arcabio.com

 
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.arcabio.com
  • 10170 Church Ranch Way Suite 100
    Westminster, CO USA 80021
  • Phone: 720.940.2100

Executives

Name Title Contact Details
Brian Selby
Chief Financial Officer Profile
Jeffrey Dekker
Chief Financial Officer Profile

Similar Companies

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Senior Care Professionals

Senior Care Professionals is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Direct

DNA Direct is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Alta Biomedical Group

Alta Biomedical Group is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.